Why do you think they should skip liver cancer? Looks a big market especially Asia , yes crowded space competition with other treatments but a small segment of big market is still worthwhile imo
agree with you point about add on, for example combine with immunotherapy (checkpoint inhibitor) is possible I think I heard somebody mentioning this once somewhere possibly old investor call
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $30.58M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 1.0¢ | 0.9¢ | $191.9K | 21.25M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 8525000 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 964494 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |